Detalhe da pesquisa
1.
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Blood
; 135(18): 1541-1547, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31978210
2.
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis.
Eur J Haematol
; 105(4): 495-501, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564450
3.
Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Biol Blood Marrow Transplant
; 25(5): e169-e173, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30639823
4.
Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Biol Blood Marrow Transplant
; 24(9): 1823-1827, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29933072
5.
Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial.
Blood
; 128(8): 1059-62, 2016 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27381904
6.
Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.
Am J Kidney Dis
; 69(2): 317-319, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27780577
7.
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Biol Blood Marrow Transplant
; 21(8): 1445-51, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25858810
8.
Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis.
Am J Hematol
; 94(7): E194-E196, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31020691
9.
Safety of autologous stem cell transplantation in patients with known Human T-cell Lymphotropic Viruses Type 1 and 2 infection: A case series of four patients.
Am J Hematol
; 94(12): E317-E319, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31489689
10.
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
Haematologica
; 98(5): 789-92, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23144200
11.
Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Transplant Cell Ther
; 29(11): 695.e1-695.e7, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37607644
12.
Understanding Amyloidosis: Unraveling the Complexities and Therapeutic Approaches for Oncology Nurses.
Clin J Oncol Nurs
; 26(4): 421-432, 2022 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35939729
13.
Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.
Am J Hematol
; 88(8): 719, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23650113